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Abstract
Background: Due to the post-mitotic nature of myonuclei, postnatal myogenesis is essential for skeletal muscle
growth, repair, and regeneration. This process is facilitated by satellite cells through proliferation, differentiation, and
subsequent fusion with a pre-existing muscle fiber (i.e., myonuclear accretion). Current knowledge of myogenesis is
primarily based on the in vitro formation of syncytia from myoblasts, which represents aspects of developmental
myogenesis, but may incompletely portray postnatal myogenesis. Therefore, we aimed to develop an in vitro
model that better reflects postnatal myogenesis, to study the cell intrinsic and extrinsic processes and signaling
involved in the regulation of postnatal myogenesis.
Methods: Proliferating C2C12 myoblasts were trypsinized and co-cultured for 3 days with 5 days differentiated C2C12
myotubes. Postnatal myonuclear accretion was visually assessed by live cell time-lapse imaging and cell tracing by cell
labeling with Vybrant® DiD and DiO. Furthermore, a Cre/LoxP-based cell system was developed to semi-quantitatively
assess in vitro postnatal myonuclear accretion by the conditional expression of luciferase upon myoblast–myotube
fusion. Luciferase activity was assessed luminometrically and corrected for total protein content.
Results: Live cell time-lapse imaging, staining-based cell tracing, and recombination-dependent luciferase activity,
showed the occurrence of postnatal myonuclear accretion in vitro. Treatment of co-cultures with the myogenic factor
IGF-I (p < 0.001) and the cytokines IL-13 (p < 0.05) and IL-4 (p < 0.001) increased postnatal myonuclear accretion, while
the myogenic inhibitors cytochalasin D (p < 0.001), myostatin (p < 0.05), and TNFα (p < 0.001) decreased postnatal
myonuclear accretion. Furthermore, postnatal myonuclear accretion was increased upon recovery from electrical pulse
stimulation-induced fiber damage (p < 0.001) and LY29004-induced atrophy (p < 0.001). Moreover, cell type-specific
siRNA-mediated knockdown of myomaker in myoblasts (p < 0.001), but not in myotubes, decreased postnatal
myonuclear accretion.
Conclusions: We developed a physiologically relevant, sensitive, high-throughput cell system for semi-quantitative
assessment of in vitro postnatal myonuclear accretion, which can be used to mimic physiological myogenesis triggers,
and can distinguish the cell type-specific roles of signals and responses in the regulation of postnatal myogenesis. As
such, this method is suitable for both basal and translational research on the regulation of postnatal myogenesis, and
will improve our understanding of muscle pathologies that result from impaired satellite cell number or function.
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Background
Skeletal muscle fibers arise from the biochemical and
morphological differentiation of muscle precursor cells.
This process is called myogenesis and is essential for
prenatal development, as well as postnatal muscle tissue
growth, maintenance, and repair.
Myogenesis during prenatal skeletal muscle development
is elaborately studied (for review, see, e.g., Buckingham et
al. [1]). Briefly, limb muscles arise from muscle progenitor
cells that are derived from the dermomyotome—the matur-
ing somite that forms from the paraxial mesoderm. Upon
external cues, muscle progenitor cells migrate into the
limb bud, proliferate, become committed to the myogenic
transcription program, differentiate biochemically and mor-
phologically, and fuse with each other to give rise to pri-
mary and secondary muscle fibers.
In postnatal skeletal muscle, muscle progenitor cells
are also present. These adult progenitor cells, called sat-
ellite cells, originate from the same dermomyotome-
derived Pax3+/Pax7+ population [2–5] and are located
between the sarcolemma and basal lamina. In the early
postnatal period, myogenesis facilitates muscle growth
by satellite cell proliferation, differentiation, and fusion
with a pre-existing muscle fiber [6], which is recapitu-
lated during adult muscle hypertrophy. However, in
healthy adult muscle, the majority of satellite cells are
quiescent. Upon external cues, adult satellite cells
become activated, proliferate, and either return to quies-
cence in a process called self-renewal, or differentiate to
fuse with a pre-existing muscle fiber (for review, see,
e.g., Dhawan et al. [7]).
Due to the post-mitotic nature of myonuclei, postnatal
myogenesis is essential for skeletal muscle maintenance,
growth, repair, and regeneration. In vivo in human skel-
etal muscle, these roles are demonstrated by the acute
increase in satellite cell activation status and number
after exercise, and the positive association between
changes in muscle fiber size, satellite cell content, and
myonuclear content after prolonged exercise training, as
reviewed by Snijders et al. [8]. The requirement of satel-
lite cells for muscle growth, repair, and regeneration has
mainly been established in animal studies. These funda-
mental studies showed that satellite cell ablation by γ-ir-
radiation or Pax7+ cell depletion prevents sustained
overload-induced muscle hypertrophy and recovery from
muscle injury [9–12]. Although subsequent work has
challenged this concept [13], more recent studies con-
firm the essential role of satellite cells in muscle growth
[14, 15].
A role for impaired myogenesis, by either a reduced
satellite cell number or function, has been implicated in
the loss of skeletal muscle mass and function (i.e.,
sarcopenia) in aging, chronic diseases, and myopathies
[16–18]. The identification of regulators and pathways
involved in postnatal satellite cell function and dysfunc-
tion is imperative for a better comprehension of the role
of myogenesis in aging and disease-related muscle loss,
and to develop targeted intervention strategies aimed at
optimizing muscle health and function.
Considerable progress has been made towards uncover-
ing these mediators and regulators of satellite cell function
in health and disease, as reviewed by Buckingham et al.
[1]. In vivo and ex vivo models were fundamental in their
identification, while knowledge on the causal role of these
mediators and regulators in myogenesis was primarily
based on in vitro culturing and differentiation of primary
satellite cells and immortalized myoblasts. This in vitro
formation of syncytia from mononucleated myoblasts
morphologically resembles developmental myogenesis,
but has also been employed as a model to study the
regulation of postnatal myogenesis [19–21]. Indeed, it was
theorized that muscle regeneration recapitulates develop-
mental myogenesis. However, based on the reported
differential requirements for β-catenin during embryonic
and fetal myogenesis [5], this theory has been challenged
[22–24]. Several reviews compared developmental and
postnatal myogenesis and found important distinctions in
the involved cells, anatomy, cellular mechanisms, and
expression of regulatory genes [22, 24, 25]. This novel
insight requires reframing of the current knowledge on
myogenesis, and reconsideration of established myogen-
esis models. Specifically, we should consider the context-
ual use of the classical in vitro model of myogenesis, i.e.,
syncytia formation from myoblasts, which may represent
developmental myogenesis, but incompletely or even
inaccurately portrays postnatal myogenesis.
The use of a more appropriate model will advance the
comprehension of regulation and dysregulation of post-
natal myogenesis and its role in the development of sar-
copenia, and is thus indispensable in the identification of
specific targets for effective prevention and treatment of
sarcopenia. In this study, we therefore aimed to develop
an in vitro model that better reflects postnatal myogen-
esis, to study the cell intrinsic and extrinsic processes
and signaling involved in the regulation of postnatal
myogenesis.
Methods
Cell culture and reagents
Cell maintenance and experiments were performed in a
humidified incubator at 37 °C with 5% CO2. C2C12
myoblasts (ATCC, Wesel, Germany; #CRL-1772) were
maintained in growth medium (GM) which was com-
posed of Dulbecco’s modified Eagle’s medium (DMEM
1 g/L glucose (Gibco, Rockville, MD; #22320-022)
supplemented with 9% (v/v) fetal bovine serum (FBS),
and 50 U/mL penicillin and 50 μg/mL streptomycin (P/S)
(Gibco). To induce differentiation, cells were plated onto
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tissue culture plates coated with 2% (v/v) Growth Factor
Reduced Matrigel® (BD Biosciences, Bedford, MA) and
switched to differentiation medium (DM) composed of
DMEM 4.5 g/L glucose (Gibco; #41966-029) supple-
mented with 0.5% (v/v) heat-inactivated FBS and P/S.
Human C25 myoblasts (HSM) [26] were kindly
provided by V. Mouly. HSM cells were maintained in
GM which was composed of Skeletal Muscle Cell
Growth Medium supplemented with 42 μg/mL bovine
Fetuin, 8.3 ng/mL human recombinant Epidermal
Growth Factor, 0.83 ng/mL human recombinant Basic
Fibroblast Growth Factor, 8.3 μg/mL human recombin-
ant Insulin, 0.33 μg/mL Dexamethasone (all from
PromoCell, Heidelberg, Germany), 17% (v/v) FBS, and
P/S. To induce differentiation, cells were plated onto
Matrigel-coated tissue culture plates and switched to DM
which was composed of DMEM 4.5 g/L glucose, Gluta-
MAX™ (Gibco; #61965-026) supplemented with P/S.
DM was replaced 24 h after initiation of differenti-
ation, and subsequently every 48 h. Myotube–myoblast
co-cultures were initiated with 5 days differentiated
myotubes and 5000 cells/cm2 myoblasts, unless indi-
cated otherwise.
For lentivirus production, 293FT cells (Invitrogen,
Carlsbad, CA; #R700-07) were maintained in DMEM
4.5 g/L glucose supplemented with 9% (v/v) FBS, P/S,
and 500 μg/mL Geneticin (Gibco).
Recombinant human insulin-like growth factor 1 (IGF-
I) (Sigma-Aldrich, Zwijndrecht, The Netherlands), recom-
binant human/mouse/rat growth differentiation factor 8
(Myostatin, MSTN), recombinant mouse interleukin-4
(IL-4) and human IL-13 (R&D systems, Minneapolis,
MN), and recombinant mouse tumor necrosis factor alpha
(TNF-α) (Merck Millipore, Amsterdam, The Netherlands)
were dissolved in 0.1% bovine serum albumin (BSA)
(Sigma-Aldrich) in Hanks’ Balanced Salt Solution (HBSS).
LY294002 (LY) (Merck Millipore) and Cytochalasin D
(CytoD) (Sigma-Aldrich) were dissolved in DMSO.
Electrical pulse stimulation
Myotubes were electrically stimulated using a C-Pace
unit and a C-Dish electrode assembly for 35 mm culture
dishes (Ion Optix, Milton, MA). Stimulation was per-
formed according to the “twitch” protocol by Orfanos et
al. [27]. Briefly, pulses were applied for 20 ms at 10 V, at
a frequency of 1 Hz.
RNA interference
Knockdown of Myomaker was achieved by RNA inter-
ference. Target Silencer® Select siRNA or negative con-
trol Silencer® Select siRNA (final 10 nM) was mixed with
Lipofectamine RNAiMAX (Invitrogen) in Opti-MEM
reduced serum medium (Gibco; #31985-070). After
complex formation at room temperature (RT) for 5 min,
the transfection mix was added to adherent cells, and
incubated for 24 h before initiation of co-culturing.
Western blot
Cells were lysed in whole cell lysis buffer (20 mM Tris,
150 mM NaCl, 1% Nonidet P40, and protease and phos-
phatase inhibitors (Roche)), incubated on ice for 30 min,
and centrifuged at 14,000g for 30 min. Total protein
concentration in the supernatant was determined using
BCA Protein Assay kit (Pierce) according to the manu-
facturer’s instructions. 4× Laemmli sample buffer
(0.25 M Tris-HCL ph 6.8, 8% (w/v) SDS, 40% (v/v)
glycerol, 0.4 M DTT, and 0.02% (w/v) Bromophenol
Blue) was added to the supernatant, and samples were
heated to 100 °C for 5 min. Protein (3 μg myoblast lys-
ate; 10 μg myotube lysate) were separated on a Criterion
XT Precast 4–12% Bis-Tris gel (Bio-Rad), followed by
transfer to a 0.45 μm nitrocellulose membrane (Bio-Rad)
by electroblotting. For total protein detection, the mem-
brane was stained with PonceauS solution (0.2%
PonceauS in 1% acetic acid; Sigma-Aldrich Chemie) and
imaged using the Amersham imager 600RGB. The mem-
brane was blocked for 1 h at RT in Tris-buffered saline
with Tween20 (20 mM Tris, 137 mM NaCl, 0.1% (v/v)
Tween20, pH 7.6 (TBST)) containing 5% (w/v) nonfat
dry milk (Campina). After washing in TBST, the mem-
brane was incubated overnight at 4 °C with 1:1000 anti-
Myomaker (NBP2-34175; Novus) diluted in TBST with
5% (w/v) BSA. Subsequently, the membrane was incu-
bated with peroxidase conjugated secondary antibody
solution (PI-1000; Vector laboratories) for 1 h at RT, and
the target was visualized by chemiluminescence using
supersignal FEMTO chemiluminescent substrate (Pierce
Biotechnology, Inc.) according to the manufacturer’s
instructions, and detected using the Amersham Imager
600RGB. Signals were quantified with Image Quant Soft-
ware (Amersham), and corrected for total protein content.
Stable transfection
The LV-floxed-Luc C2C12 cell line expresses a conditional
luciferase cassette dependent on Cre-mediated recombin-
ation, and was generated by Lipofectamine® 2000 (Invitro-
gen) mediated transfection with LV-floxed-Luc (Addgene,
Cambridge, MA; #60622) and subsequent selection based
on a selectable marker.
The Cre C2C12 cell line expresses Cre recombinase,
and was obtained by lentivirus-mediated infection with
Cre-IRES-PuroR (Addgene; #30205). Lentiviral super-
natant was produced by polyethylenimine-mediated
co-transfection of 293FT cells with Cre-IRES-PuroR,
pRSV-Rev (Addgene; #12253), pMDLg/pRRE (Addgene;
#12251), and pMD2.G (Addgene; #12259) (1:1:1:1) in
C2C12 GM. Lentivirus supernatant was collected 24, 48,
and 72 h after transfection, filter sterilized (0.45 μM),
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and stored at − 20 °C. C2C12 cells were infected by
addition of lentiviral supernatant in GM (1:1) containing
1 μg/mL polybrene (Sigma-Aldrich), and subsequently
selected based on a selectable marker.
Stable polyclonal cell lines were expanded, and stored
in liquid nitrogen. For each experiment, a new vial was
used to reduce variability between experiments.
Cell staining and hybrid quantification
C2C12 or HSM cells were subjected to live staining with
Vybrant® DiD or DiO cell labeling solution (Life Tech-
nologies, Carlsbad, CA) before plating. Briefly, myoblasts
were stained in suspension in GM at 37 °C for 20 min,
and washed three times by pelleting and resuspension in
GM. To obtain stained myotubes, stained myoblasts
were plated and differentiated as described. Subse-
quently, co-culturing was initiated, and after 2 days, cell
monolayers were washed with HBSS and fixed in 3.7%
paraformaldehyde (PFA). After fixation, nuclei were
stained with DAPI and coverslips were mounted onto
the cell monolayers using Mowiol/DABCO.
Images were taken at a 100× magnification using an
Eclipse E800 microscope (Nikon) connected to a digital
camera (DXM, 1200 NF, Nikon). For quantification of
hybrid formation, five random fields of view (FOV) were
captured from each well. Myotubes (i.e., cells with ≥ 3
nuclei) containing both DiD and DiO cell tracers, result-
ing from myonuclear accretion, were defined as hybrids.
Total myotubes and hybrid myotubes were counted, and
hybrids were expressed as percentage of the total num-
ber of myotubes. The sum of five images was used to
represent each well.
BrdU labeling and immunohistochemical detection
C2C12 myoblasts were incubated with 10 μM bromo-
deoxyuridine (BrdU) (Sigma-Aldrich) in GM for 24 h,
and subsequently co-cultured with 5 days differentiated
myotubes.
At the indicated time points, cells were fixed in 3.7%
PFA, and subsequently permeabilized with 0.1% Triton
X-100 (Sigma-Aldrich) in phosphate buffered saline
(PBS). Fixed cells were denatured with 1 N HCL in PBS
for 30 min at 45 °C, and neutralized with 0.1 M borate
buffer (pH 8.5) for 10 min at RT. After 1 h incubation
with blocking buffer (1% BSA, 22.52 mg/ml glycine,
0.1% Tween in PBS (PBST)), cells were incubated over-
night with rat monoclonal anti-BrdU antibody (Abcam;
#ab6326) (1:75 in 1% BSA in PBS) at 4 °C in a humidi-
fied chamber, and then incubated for 1 h with rabbit
anti-rat antibody (Abcam; #ab6730) (1:200 in 1% BSA in
PBS) at RT in the dark. Nuclei were subsequently
stained with DAPI, and coverslips were mounted onto
the cell monolayers using Mowiol/DABCO. Images were
taken at a 100× magnification using an Axio Observer
A1 microscope (Zeiss) connected to a digital camera
(AxioCam ICM1, Zeiss). From each well, five random
FOV were captured, and BrdU+ nuclei (staining positive
for BrdU and DAPI) in myotubes (i.e., cells with ≥ 3
nuclei) were counted. The sum of five images was used
to represent each well.
Luciferase detection
Cell monolayers of Cre and LV-floxed-Lux C2C12
co-cultures were lysed in reporter lysis buffer (Promega,
Madison, WI) by scraping and a subsequent freeze-thaw
cycle, and briefly centrifuged to remove cell debris.
Luciferase activity was measured by addition of 100 μL
luciferase assay reagent (1.07 mM MgCO3, 2.67 mM
MgSO4, 20.0 mM Tricin, 0.10 mM EDTA, 33.3 mM
DTT, 530 μM ATP, 270 μM Coenzyme A, 470 μM
Luciferin) to 20 μL lysate, and subsequent luminescence
detection using a single tube luminometer (Lumat LB
9507, Berthold, Bad Wildbad, Germany), according to
the manufacturer’s protocol (Promega). The lumines-
cence signal (RLU) was corrected for total protein
content in the soluble fraction assessed by a BCA pro-
tein assay (Pierce Biotechnology, Rockford, IL).
Statistics
Data are presented as means ± SEM and are representa-
tive of ≥ 3 independent experiments. Analyses were per-
formed using SPSS Statistics (version 22.0, IBM Corp.,
Armonk, NY). Comparisons between two groups were
performed using an independent student’s t-test.
Comparisons between > 2 groups were performed by
one-way ANOVA with Bonferroni post hoc correction.
A p value < 0.05 was considered statistically significant.
Results
In vitro fusion of myoblasts with myotubes
The classical in vitro myogenesis model entails the for-
mation of syncytia from myoblasts. To better mimic
postnatal myogenesis in vitro, we sought to represent
the involved fusion partners. To this end, myotubes
obtained by 5-day differentiation of C2C12 myoblasts
were co-cultured with yet undifferentiated myoblasts.
Through live cell time-lapse, imaging fusion of myo-
blasts with myotubes was observed during the 48 h after
initiation of co-culturing (Additional file 1; Additional
file 2: Figure S1). Accordingly, the fusion of DiO-stained
C2C12 myoblasts with DiD-stained myotubes resulted in
the formation of hybrid myotubes (Fig. 1), and in vitro
myotube–myoblast fusion was confirmed in a similar
experiment in HSM cells (Additional file 3: Figure S2).
Together, this shows that both C2C12 and HSM cells
are capable of in vitro postnatal myonuclear accretion.
(Additional file 1).
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In vitro postnatal myonuclear accretion is increased by
IGF-I
Staining-based quantification was optimized (Additional
file 4: Figure S3), and used to assess if the number of in
vitro postnatal myonuclear accretion events can be
modified. Co-cultures were treated with IGF-I, repre-
senting a well-established myogenic factor, which
impacts on both proliferation and differentiation [28].
This revealed a higher total amount of myotubes, a higher
total amount of hybrids, and a higher relative amount of
hybrids 2 days after initiation of co-culturing in the pres-
ence of IGF-I (Fig. 2a–c). IGF-I treatment started 24 h
after initiation of co-culturing had no effect, whereas 24-h
pre-treatment with IGF-I increased the number of myo-
tubes but did not affect the relative amount of hybrid
myotubes (Additional file 5: Figure S4). This showed that
the staining-based method had sufficient power to detect
relevant differences in postnatal myonuclear accretion.
Furthermore, the staining-based method displayed a sig-
nificant inter-rater correlation and a moderate to high
inter-rater agreement (Additional file 6: Figure S5).
However, Bland-Altman analysis revealed a significant
fixed bias for both the absolute and relative amount of
hybrids, and potentially clinically relevant differences may
lie within the 95% limits of agreement (Additional file 6:
Figure S5D, F). Moreover, the staining-based assessment
of postnatal myonuclear accretion was labor intensive and
time consuming. For unbiased, high throughput, semi-
quantitative assessment of postnatal myonuclear accretion,
we therefore developed a Cre/LoxP-based cell fusion
reporter system (Additional file 7: Figure S6), which allows
the conditional expression of luciferase after myoblast–
Fig. 1 In vitro myoblast–myotube fusion. Hybrid formation in DiD-stained C2C12 myotubes 2 days after initiation of co-culturing with DiO-stained
C2C12 myoblasts. (DAPI/nuclei: blue; DiD: red; DiO: green). Arrows indicate non-hybrid myotubes, arrow heads indicate hybrid myotubes
a b c
d e f
Fig. 2 Increased in vitro postnatal myonuclear accretion in C2C12 cells upon IGF-I treatment. a-c Staining-based assessment of myonuclear accretion 2 days
after initiation of co-culturing +/- 10 nM IGF-I. a total number of myotubes, b number of hybrid myotubes, c % hybrid myotubes. d-f Luciferase-based
assessment of myonuclear accretion 3 days after initiation of co-culturing +/− 10 nM IGF-I. D) luciferase activity (RLU) per well, E) protein content (μg/μL)
per well, F) relative luciferase activity (RLU/protein content) per well. Values are means ± SEM, n= 4. *p< 0.05, **p< 0.01, ***p< 0.001
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myotube fusion. IGF-I treatment of LV-floxed-Luc
myotubes and Cre myoblast co-cultures increased protein
content and absolute luciferase activity, but no change in
the relative luciferase activity was observed. However,
IGF-I treatment of Cre myotube and LV-floxed-Luc
myoblast co-cultures resulted in an increased protein
content, and increased relative and absolute luciferase
activity in cells lysed 3 days after initiation of co-culturing
(Fig. 2d–f, Additional file 7: Figure S6F−H), indicating
increased cell fusion.
The Cre/LoxP-based cells system was further charac-
terized by employing co-cultures with increasing con-
centrations of IGF-I. A dose-dependent increase in the
relative luciferase activity and total protein content was
observed upon treatment with increasing concentrations
of IGF-I (Additional file 8: Figure S7 d−f ). To verify
IGF-I stimulated myonuclear accretion, the incorpor-
ation of BrdU-labeled myoblast nuclei into myotubes
was assessed. A dose-dependent increase in the number
of BrdU+ nuclei in myotubes was observed upon
treatment with IGF-I, which had a strong, but non-
significant correlation with the change in relative lucifer-
ase activity (Additional file 8: Figure S7 G−I). To further
validate luciferase activity in the Cre/LoxP-based model
as an index of fusion, the stimulatory effects of IGF-I on
protein synthesis- and fusion-dependent luciferase
expression were dissected. Cre and LV-floxed-Luc myo-
blasts were co-cultured and differentiated into hybrid
myotubes with constitutive luciferase expression, and
their subsequent time- and dose-dependent luciferase
activity in response to IGF-I was compared to myoblast-
myotube co-cultures (Additional file 9: Figure S8).
Although IGF-I treatment increased the relative lucifer-
ase activity at T = 72 in both systems, the magnitude of
the effect in the preformed hybrid myotubes was
negligible compared to that observed in fusion-
dependent luciferase expressing co-cultures (Additional
file 9: Figure S8).
In vitro postnatal myonuclear accretion is reduced by
cytochalasin D, myostatin and TNFα
To assess if the rate of in vitro postnatal myonuclear ac-
cretion can be suppressed, co-cultures were treated with
known inhibitors of myogenesis: CytoD, MSTN and
TNFα. CytoD treatment upon initiation of co-culturing
resulted in a reduction of luciferase activity to back-
ground levels measured in myotube only cultures, and a
small increase in total protein content (Fig. 3a–c).
MSTN treatment upon initiation of co-culturing had no
effect on the protein content, but led to a decrease in
absolute and relative fusion reporter activity (Fig. 3d–f ).
Similarly, TNFα treatment upon initiation of co-culturing
led to a decrease in absolute and relative fusion reporter
activity, in presence of an increase in the total protein
content per well (Fig. 3g–i). Suppression of fusion reporter
activity by TNFα treatment was dose-dependent
(Additional file 8: Figure S7 A−C). Moreover, when
applied to preformed hybrid myotube cultures no de-
crease in absolute or negative luciferase content was
detected in response to TNFα (Additional file 9: Figure S8
D−F), suggesting reduced fusion-dependent luciferase
expression in myoblast-myotube co-cultures (Fig. 3g−i)
rather than decreased synthesis of luciferase protein.
In vitro postnatal myonuclear accretion is increased by
the anti-inflammatory cytokines IL-13 and IL-4
In contrast to the pro-inflammatory cytokine TNFα,
the anti-inflammatory cytokines IL-13 and IL-4 have
been identified as promoting factors for postnatal
myogenesis [29, 30]. IL-13 treatment upon initiation
of co-culturing resulted in an increase in the total
protein content and an increase in the absolute and
relative fusion reporter activity (Fig. 4a–c). Similarly,
IL-4 treatment tended to increase the total protein
content and led to an increase in the absolute and
relative fusion reporter activity (Fig. 4d–f ).
In vitro postnatal myonuclear accretion is increased upon
recovery from myotube injury and atrophy
Physiological conditions that trigger in vivo postnatal
myonuclear accretion include the recovery from muscle
damaging exercise such as eccentric exercise and the
recovery from muscle atrophy. In vitro myotube damage
induced by electrical pulse stimulation (EPS) followed by
recovery in the presence of myoblasts led to an in-
creased total protein content and increased absolute and
relative fusion reporter activity compared to untreated
co-cultures (Fig. 5a–c). In vitro induction of atrophy by
LY pre-treatment and maintenance during co-culturing
led to a significant decrease in the total protein content
and a decrease in the absolute and relative fusion
reporter activity (Fig. 5d–f ). Furthermore, removal of LY
upon initiation of co-culturing led to a normalization of
the total protein content and an increase in the absolute
and relative fusion reporter activity compared to main-
tained LY stimulation and control (Fig. 5d–f ).
In vitro postnatal myonuclear accretion requires the
expression of Myomaker in myoblasts
A novel factor involved in myogenic fusion that is
required for muscle regeneration and hypertrophy is
Myomaker [15, 31]. A cell type-specific differential re-
quirement of Myomaker has been reported [32]. We
assessed if the requirement of Myomaker for fusion is
myoblast or myotube specific. SiRNA-mediated knock-
down of Myomaker was verified and resulted in a strong
reduction in Myomaker protein abundance in myotubes,
whereas Myomaker expression was below the detection
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limit in myoblasts (Fig. 6d, e). Knockdown of Myomaker in
myotubes did not alter the absolute and relative cell fusion
reporter activity in co-cultures (Fig. 6a−c). In contrast, treat-
ment of myoblasts with siRNA against Myomaker decreased
both the absolute and relative fusion reporter activity in co--
cultures containing Myomaker-expressing or -silenced myo-
tubes (Fig. 6a−c). These data indicate that Myomaker
expression in myoblasts is required for cell fusion.
Discussion
The requirement for postnatal myogenesis in muscle
growth, repair and regeneration, and basal muscle main-
tenance is evident from research in humans [8, 33, 34]
and rodents [9–12, 35]. However, data on the regulation
and dysregulation of postnatal myonuclear accretion is
scarce due to the technical challenge to investigate and
quantitate this process in vivo and in vitro. Although,
d e f
g h i
a b c
Fig. 3 Decreased in vitro postnatal myonuclear accretion in C2C12 cells upon CytoD, MSTN and TNFα treatment. Luciferase-based assessment of
myonuclear accretion 3 days after initiation of co-culturing +/- 0.3 μM CytoD (A-C), 250 ng/mL MSTN (D-F), or 10 ng/mL TNFα (G-I). a Luciferase activity
(RLU) per well, b protein content (μg/μL) per well, c relative luciferase activity (RLU/protein content) per well, d luciferase activity (RLU) per well, e protein
content (μg/μL) per well, f relative luciferase activity (RLU/protein content) per well, g luciferase activity (RLU) per well, h protein content (μg/μL) per well, i
relative luciferase activity (RLU/protein content) per well. Values are means ± SEM, n= 4. *p< 0.05, **p< 0.01, ***p< 0.001
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myoblast–myotube fusion is frequently mentioned in lit-
erature, the majority of these in vitro studies actually
refer to late myogenesis in progressively differentiating
cultures. Certainly, these classical studies have provided
invaluable insights in the regulation and dysregulation of
myogenesis, however, their translatability to adult skel-
etal muscle maintenance can be challenged [5, 22–24].
In the current study, we developed an unbiased, high
throughput, Cre/LoxP-based in vitro model system for
semi-quantitative assessment of postnatal myonuclear
accretion. This model builds on the broadly employed
classical model of myogenesis, by including the fusion
partners involved in in vivo postnatal myonuclear accre-
tion through co-culturing of differentiated C2C12 myo-
tubes with yet undifferentiated C2C12 myoblasts. Via
live cell time-lapse imaging, staining-based cell tracing,
and recombination-dependent luciferase activity, we
show that postnatal myonuclear accretion occurs in
vitro. This finding is in line with the scant previous
studies assessing myoblast–myotube fusion in co-
cultures by staining-based cell tracing [30, 36–39].
Furthermore, we reproduced this finding in a HSM cell
line, and thereby confirm that in vitro myoblast–myo-
tube fusion is not a C2C12 cell line specific anomaly.
Using this co-culture model, a substantial number of hy-
brid cells and a pronounced luciferase signal are detected
even in the absence of an additional myogenic trigger.
Although previous literature states that in uninjured adult
muscles, satellite cells are mitotically quiescent [12], in
line with our data, a more recent study challenged this
proposed low basal myonuclear turnover rate and shows
that a significant percentage of satellite cells divide and
fuse in uninjured adult muscles [40]. Differences in
observed “basal” myonuclear turnover rates may arise
from variations in the employed methodologies. Import-
antly, satellite cells were reported to rapidly activate in
explant cultures [41], which resembles the proliferative
state of myoblasts in our co-culture model.
a b c
d e f
Fig. 4 Increased in vitro postnatal myonuclear accretion in C2C12 cells upon IL-13 and IL-4 treatment. Luciferase-based assessment of myonuclear
accretion 3 days after initiation of co-culturing +/− 250 ng/mL IL-13 (a-c) or 500 ng/mL IL-4 (d-f). a Luciferase activity (RLU) per well, b protein
content (μg/μL) per well, c relative luciferase activity (RLU/protein content) per well, d luciferase activity (RLU) per well, e protein content (μg/μL)
per well, f relative luciferase activity (RLU/protein content) per well. Values are means ± SEM, n = 4. *p < 0.05, ***p < 0.001
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Based on the basal luciferase signal and the respon-
siveness of the Cre/LoxP-based reporter system with Cre
and LV-floxed-Luc C2C12 alternating as acceptor and
donor cells for myonuclear accretion, we conclude that
co-culturing of Cre myotubes with LV-floxed-Luc myo-
blasts most sensitively reports fusion (Additional file 7:
Figure S6). This likely reflects the recombination-
dependent increase in luciferase expression in Cre myo-
tubes with the incorporation of every additional nucleus
derived from an LV-floxed-Luc myoblast, whereas accre-
tion of one single nucleus derived from a Cre myoblast
may result in the recombination of multiple nuclei
d e f
a b c
Fig. 5 Increased in vitro postnatal myonuclear accretion in C2C12 cells upon recovery from myotube damage and atrophy. Luciferase-based assessment
of myonuclear accretion 3 days after initiation of co-culturing of myotubes pre-treated by 1-h electrical pulse stimulation, with myoblasts in presence of
conditioned medium (n= 6). a Luciferase activity (RLU) per well, b protein content (μg/μL) per well, c relative luciferase activity (RLU/protein content) per
well. Luciferase-based assessment of myonuclear accretion 3 days after initiation of co-culturing of myotubes pre-treated +/- 15 μM LY (24 h pre), with
myoblasts in presence or absence of 15 μM LY (72 h post) (n = 4). d luciferase activity (RLU) per well, e protein content (μg/μL) per well, f relative luciferase
activity (RLU/protein content) per well. T = initiation and duration of treatment (h) relative to start of co-culturing. Values are means ± SEM, n= 4. *p< 0.05,
**p< 0.01, ***p< 0.001 compared to control or between indicated groups
cba
d e
Fig. 6 Myomaker is specifically required in myoblasts for in vitro postnatal myonuclear accretion in C2C12 cells. Luciferase-based assessment of
myonuclear accretion 3 days after initiation of co-culturing of myotubes (MT) with myoblasts (MB) which received 24-h pre-treatment with either
negative control siRNA (siNeg) or siRNA against Myomaker (siMyo) (n = 4). a Luciferase activity (RLU) per well, b protein content (μg/μL) per well,
c relative luciferase activity (RLU/protein content) per well. Parallel experiment of siRNA treated MT and MB, maintained in separate cultures. d
Western blot of Myomaker, e densitometric analysis of 20 kDa band (n = 8). Values are means ± SEM. ***p < 0.001 compared to control
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present in one LV-floxed-Luc myotube. We show that in
this model, IGF-I induces a profound increase in postna-
tal myonuclear accretion. IGF-I is a well-established
driver of muscle hypertrophy that has been associated
with increases in both protein synthesis and myogenesis
[42]. In line with this, IGF-I treatment during co-cultur-
ing increases the total protein content, as well as cell fu-
sion assessed by staining-based and reporter-based
fusion quantification. In agreement with previous litera-
ture [42], the effect of IGF-I depends on the timing of
treatment initiation, which may suggest a role for tem-
poral IGF-I expression during postnatal myogenesis.
Furthermore, we show that TNFα treatment decreases
postnatal myonuclear accretion. This disease-related fac-
tor was previously shown to reduce the myogenic index
[19]. Although we demonstrate a dose-dependent de-
crease in fusion upon increasing TNFα concentrations, a
bimodal effect of TNFα treatment was found when
lower concentrations were included [43]. Furthermore,
positive effects of TNFα on proliferation have been
reported [44], which may explain the increase in total
protein content in TNFα-treated co-cultures.
These modulatory effects of IGF-I and TNFα show
that the Cre/LoxP-based fusion reporter system is
responsive to physiologically relevant ligands that modu-
late myogenesis. Furthermore, the IGF-I and TNFα-dose
dependent (Additional file 8: Figure S7 A−F), and the
myoblast-density dependent (Additional file 7: Figure S6
E) effects on the relative luciferase activity, together with
the lag time for effects of modulations to result in
changes in luciferase activity (Additional file 7: Figure S6
F−H, Additional file 9: Figure S8 A−C), suggest that the
relative luciferase activity is reflecting fusion. Moreover,
in keeping with previous research [32, 45], treatment of
co-cultures with CytoD reduces the luciferase reporter
activity to background levels, verifying that luciferase re-
porter activity in our system requires cell fusion. In line,
the stimulation of luciferase activity corresponds with an
increased presence of myoblast-derived myonuclei in
myotubes, providing further support that alterations in
luciferase activity are determined by, and therefore re-
flect fusion. Nevertheless, the absolute luciferase activity
is a product of post-recombinational luciferase expres-
sion, which may be affected by alterations in cellular
transcriptional and translational activity. To disentangle
effects on fusion and protein synthesis, we compared the
time-dependent effects of IGF-I and TNFα on fusion-
dependent luciferase expressing co-cultures, and Cre
and LV-floxed-Luc hybrid myotubes with constitutive
luciferase expression, respectively (Additional file 9:
Figure S8). Based on the large difference in the magni-
tude of the effect of IGF-I, and the difference in the
direction of the effect of TNFα on the relative luciferase
activity, we conclude that changes in the relative
luciferase activity in the Cre/LoxP-based fusion reporter
system are indeed mainly dictated by changes in fusion.
Nevertheless, when the absolute rate of myonuclear
accretion is of interest, luciferase-based screening should
be followed up by quantitative assessment of myonuclear
accretion, e.g., by staining-based nuclear tracing of BrdU
labeled myoblasts.
The current method reports the cumulative functional
contribution of fusion events, and may thereby facilitate
the elucidation of the homeostatic control of myonuclear
number, which is of particular interest for the slow
progressive muscle wasting seen in aging [8], chronic
diseases [46], and muscle dystrophy [47]. However,
luciferase-based reporting of fusion operates with a cer-
tain lag time, determined by recombination, transcrip-
tion, and translation of the reporter gene. Therefore, no
complete distinction can be made between alterations in
the amount or rate of myonuclear accretion, although
both may be equally relevant. To gain a more mechanis-
tic insight in the regulation of postnatal myonuclear
accretion, the current method should be used in con-
junction with assays for proliferation and biochemical
differentiation, to distinguish between effects on those
processes and fusion, as alterations in any of these pro-
cesses will affect myonuclear accretion. Furthermore, it
should be taken into account that long-term monitoring
of in vitro myonuclear accretion is restricted by the
limited cell viability in culture. Moreover, in contrast to
the staining-based assessment of in vitro postnatal myo-
nuclear accretion, Cre/LoxP-based assessment does not
provide any insight in the intermediate morphological
states of myoblasts before fusion with a myotube. Thus,
although we refer to myoblast-myotube fusion, we can-
not exclude the occurrence nor assess the relevance of,
e.g., myoblast-myoblast fusion before fusion with a pre-
existing myotube. Nevertheless, a major advantage of the
Cre/LoxP-based system is that it does not rely on visual
identification of individual myotubes which is labor in-
tensive and complex due to irregular myotube structure,
and it may therefore also be suitable to study postnatal
myonuclear accretion in, e.g., 3D culture systems [48].
In an initial utilization of the model, we assessed
pharmacological and physiological modulators of post-
natal myonuclear accretion. Similar to IGF-I [49, 50],
MSTN modulation is part of the exercise recovery
response [51, 52]. Treatment of co-cultures with the
myogenic inhibitor MSTN results in a pronounced
reduction of cell fusion, which is in agreement with
previous studies that show a reduction in the myogenic
index by treatment with MSTN [21, 53]. Furthermore,
cytokine secretion is induced during physiological
conditions that are accompanied by myonuclear accre-
tion [52, 54], such as recovery from eccentric exercise
and recovery from muscle atrophy. In contrast to the
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inhibitory effect of the pro-inflammatory cytokine TNFα
on myogenesis, the anti-inflammatory cytokines IL-13
and IL-4 have been reported to increase fusion by acting
as recruitment factors for muscle growth [29, 30]. In line
with this, we find an increase in the relative fusion
reporter activity upon co-culture treatment with IL-4
and IL-13. Furthermore, during the recovery phase after
simulation of muscle damaging exercise in vitro through
electrical pulse stimulation [27], we observe an increase
in myonuclear accretion. Moreover, upon induction of in
vitro muscle atrophy by treatment with the Pi3K
inhibitor LY [55], in line with previous research [56], a
reduction in myonuclear accretion in the presence of LY
is observed, which may reflect a requirement of IGF-I/
AKT signaling in one of the myogenic processes leading
to myonuclear accretion. Interestingly, myonuclear
accretion is increased during recovery from myotube
atrophy upon removal of LY, illustrating that myonuclear
accretion can be determined by myotube intrinsic prop-
erties, and suggesting a role of myonuclear accretion in
restoring myofiber size.
In vivo, contraction-induced muscle damage and
muscle atrophy are processes that affect the adult myofi-
ber. However, the subsequent satellite cell response dur-
ing muscle recovery suggests that crosstalk occurs
between muscle fibers and satellite cells. Importantly,
the current model system allows the separate treatment
of myotubes and myoblasts, and thereby provides the
possibility to disentangle cell type-specific signals and
responses, and facilitates exploration of their role in the
regulation of postnatal myogenesis. We exploited this
distinctive capacity by assessing whether Myomaker, a
recently identified regulator of fusion, is required for
postnatal myonuclear accretion in a cell-type specific
manner. To this end, we knocked down Myomaker in
myotubes and/or myoblasts before initiation of co-
culturing, and report a myoblast specific requirement of
Myomaker for postnatal myonuclear accretion. This is in
line with an early Myomaker study, which reported a
cell-type specific differential requirement of this protein
in myoblasts–fibroblasts fusion [32], and a more recent
study, which reported a satellite cell-specific require-
ment for Myomaker in overload-induced muscle hyper-
trophy [15].
Conclusions
In summary, we developed a Cre/LoxP-based in vitro
model that better reflects postnatal myogenesis by
including the relevant fusion partners, and can be used
for semi-quantitative assessment of postnatal myonuc-
lear accretion. We show that this model is responsive to
known ligands with myogenesis inducing and inhibiting
properties, as well as physiological triggers that affect
postnatal myonuclear accretion. Moreover, this model
allows the distinction the cell type-specific roles of sig-
nals and responses in the regulation of postnatal myo-
genesis. Together, these features make the Cre/LoxP-
based in vitro model of postnatal myonuclear accretion
suitable for both basal research on the molecular regula-
tion of postnatal myogenesis, as well as translational re-
search on the whole range of muscle diseases that may
involve impaired satellite cell number or function.
Additional files
Additional file 1: Live cell time-lapse imaging. In vitro myoblast–myotube
fusion captured by live cell time-lapse imaging. Days and hh:mm indicate
time after initiation of myotube-myoblast co-culture. (AVI 213275 kb)
Additional file 2: Figure S1. Selected frames depicting in vitro
myoblast–myotube fusion captured by live cell time-lapse imaging. Arrow
head indicates myoblast movement, and subsequent fusion with a myotube. T=
time (hh:mm) after initiation of myotube-myoblast co-culture. (EPS 14309 kb)
Additional file 3: Figure S2. Hybrid formation in DiD-stained HSM
myotubes 2 days after initiation of co-culturing with DiO-stained HSM
myoblasts. (DAPI/nuclei: blue; DiD: red; DiO: green). Arrows indicate non-
hybrid myotubes, arrow heads indicate hybrid myotubes. (EPS 38624 kb)
Additional file 4: Figure S3. Moving average and variation per well by
increasing number of fields of view (FOV). A) moving average of total
number of myotubes per well in well 1 (left) and well 2 (right), B) moving
average of number of hybrid myotubes per well in well 1 (left) and well
2 (right), C) moving average of % hybrid myotubes per well in well 1
(left) and well 2 (right). (EPS 1757 kb)
Additional file 5: Figure S4. Staining-based assessment of myonuclear
accretion 2 days after initiation of co-culturing +/- 10 nM IGF-I treatment
started 24 hours before start of co-culturing (T=-24), upon co-culturing
(T=0), or 24 hour after start of co-culturing (T=24) (A-C). A) total number
of myotubes, B) number of hybrid myotubes, C) % hybrid myotubes. Values are
means ± SEM, n= 4. *p< 0.05, **p< 0.01, ***p< 0.001 compared to control.
(EPS 816 kb)
Additional file 6: Figure S5. Inter-rater reliability of staining-based
assessment of postnatal myonuclear accretion. A) scatter plot of total
number of myotubes per well by observer 1 and observer 2, B) Bland-Altman
plot of total number of myotubes per well, C) scatter plot of number of hybrid
myotubes per well by observer 1 and observer 2, D) Bland-Altman plot of
number of hybrid myotubes per well, E) scatter plot of % hybrid myotubes
per well by observer 1 and observer 2, F) Bland-Altman plot of % hybrid
myotubes per well. Means (solid line), and the 95% confidence interval (95%
CI) and 95% limits of agreement (95% LOA) (dotted line) are displayed. Inter-
rater correlation was tested by Pearson correlation (R2), absolute inter-rater
agreement was assessed by two-way mixed model intraclass correlation
coefficient (ICC) with 95% CI, and fixed bias was assessed by Bland-Altman
analysis and tested by one sample t test. ***p< 0.001. (EPS 1837 kb)
Additional file 7: Figure S6. Optimization of Cre/LoxP-based
assessment of myonuclear accretion. Co-culture of LV-floxed-Luc C2C12
myotubes with Cre C2C12 myoblasts (A–D). A) relative luciferase activity
(RLU/protein content) per well 2 days after addition of 0, 2500, 5000 or
10000 myoblasts/cm2 (n = 3). Cells lysed at indicated time points (h) after
initiation of co-culturing +/- 10 nM IGF-I (n = 8), B) luciferase activity
(RLU) per well, C) protein content (μg/μL) per well, D) relative luciferase
activity (RLU/protein content) per well. Co-culture of Cre C2C12 myotubes
with LV-floxed-Luc C2C12 myoblasts (E-H). E) relative luciferase activity
(RLU/protein content) per well 2 days after addition of 0, 2500, 5000, or
10000 myoblasts/cm2 (n = 3). Cells lysed at indicated time points (hours)
after initiation of co-culturing +/- 10 nM IGF-I (n = 8), F) luciferase activity
(RLU) per well, G) protein content (μg/μL) per well, H) relative luciferase
activity (RLU/protein content) per well. Values are means ± SEM.
*p < 0.05, **p < 0.01, ***p < 0.001 compared to 0 cells/cm2 or compared
to T = 16 within each condition, and between indicated bars. (EPS 2309 kb)
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Additional file 8: Figure S7. Validation of Cre/LoxP-based luciferase
production as a reporter of myonuclear accretion. Co-culture of Cre
C2C12 myotubes with LV-floxed-Luc C2C12 myoblasts. Cells lysed 3 days
after initiation of co-culturing +/- increasing concentrations of TNFα
(n = 4) (A-C), A) luciferase activity (RLU) per well, B) protein content (μg/
μL) per well, C) relative luciferase activity (RLU/protein content) per well.
Cells lysed 3 days after initiation of co-culturing +/- increasing concentrations
of IGF-I (n= 4) (D-F), D) luciferase activity (RLU) per well, E) protein content
(μg/μL) per well, F) relative luciferase activity (RLU/protein content) per well. G)
myonuclear accretion of BrdU+ myoblast nuclei into myotubes, 3 days after
initiation of co-culturing (DAPI/nuclei: blue; BrdU: green). Arrows indicate ex-
amples of BrdU+ myoblast nuclei, arrow head indicates a BrdU+ nucleus in
a myotube. H) Average number of BrdU+ nuclei in myotubes per well 3
days after initiation of co-culturing +/- 10 nM IGF-I, 50 nM IGF-I, or 100 nM
IGF-I. I) scatter plot of the relative luciferase signal (RLU/protein content) and
BrdU+ nuclei in myotubes, 3 days after initiation of co-culturing +/- 10 nM
IGF-I, 50 nM IGF-I, or 100 nM IGF-I. Abbreviations: rP, Pearson correlation
coefficient; rS, Spearman correlation coefficient. Values are means ± SEM.
*p < 0.05, **p < 0.01, ***p < 0.001 compared to control; #p < 0.1 for
correlations. (EPS 3620 kb)
Additional file 9: Figure S8. Dissection of effects of alterations in fusion,
and protein synthesis on the fusion reporter activity. Co-culture of Cre C2C12
myotubes with LV-floxed-Luc C2C12 myoblasts (A-C). Cells lysed at indicated
time points (hours) after initiation of co-culturing +/- 10 ng/mL TNFα, 10 nM
IGF-I, or 50 nM IGF-I (n= 4), A) luciferase activity (RLU) per well, B) protein
content (μg/μL) per well, C) relative luciferase activity (RLU/protein content)
per well. Cre/LV-floxed-Luc C2C12 myotubes obtained by 5 days co-culturing
of Cre C2C12 and LV-floxed-Luc C2C12 myoblasts (D-E). Cells lysed at indicated
time points (hours) after start of incubation +/- 10 ng/mL TNFα, 10 nM IGF-I,
or 50 nM IGF-I (n= 4), D) luciferase activity (RLU) per well, E) protein content
(μg/μL) per well, F) relative luciferase activity (RLU/protein content) per well.
Values are means ± SEM. Results 2-way ANOVA (treatment × time); A) treat-
ment effect***, time effect***, interaction***, B) treatment effect*, time ef-
fect***, interactionns, C) treatment effect***, time effect***, interaction***, D)
treatment effect***, time effect***, interactionns, E) treatment effect***, time
effect***, interaction*, F) treatment effect***, time effect***, interaction*. Post-
hoc analyses with Bonferroni correction are depicted in the figures, *p < 0.05,
**p < 0.01, ***p < 0.001 compared to control within each time-point.
(EPS 1411 kb)
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